openPR Logo
Press release

Investigation announced for Investors in shares of Atreca, Inc. (NASDAQ: BCEL)

03-18-2020 10:52 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

An investigation for investors in Atreca, Inc. (NASDAQ: BCEL) shares over potential securities laws violations by Atreca, Inc.

An investigation for investors in Atreca, Inc. (NASDAQ: BCEL) shares over potential securities laws violations by Atreca, Inc.

An investigation was announced on behalf of investors of Atreca, Inc. (NASDAQ: BCEL) shares over potential securities laws violations by Atreca, Inc.

Investors who purchased shares of Atreca, Inc. (NASDAQ: BCEL), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm focuses on whether a series of statements by Atreca, Inc. (NASDAQ: BCEL regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Redwood City, CA based Atreca, Inc., a biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types.
On or around June 19, 2019, Atreca, Inc. conducted its initial public offering ("IPO"), issuing 7,350,000 shares of common stock priced at $17.00 per share.

Shares of Atreca, Inc. reached as high as $29.35 per share on March 4, 2020.

Theon, on March 11, 2020, Atreca, Inc. announced its financial results for the fourth quarter and full year ended December 31, 2019. Among other results, Atreca, Inc. reported fourth quarter GAAP earnings per share of -$0.72, falling $0.03 short of consensus estimates.

Shares of Atreca, Inc. (NASDAQ: BCEL) declined to as low as $10.88 per share on March 18, 2020.

Those who purchased shares of Atreca, Inc. (NASDAQ: BCEL) have certain options and should contact the Shareholders Foundation.

Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Investigation announced for Investors in shares of Atreca, Inc. (NASDAQ: BCEL) here

News-ID: 1974431 • Views:

More Releases from Shareholders Foundation

Lawsuit Alert: Investors who lost money with James Hardie Industries plc (NYSE: JHX) should contact the Shareholders Foundation
Lawsuit Alert: Investors who lost money with James Hardie Industries plc (NYSE: …
An investor, who purchased shares of James Hardie Industries plc (NYSE: JHX), filed a lawsuit over alleged violations of Federal Securities Laws by James Hardie Industries plc in connection with certain allegedly false and misleading statements. Investors who purchased shares of James Hardie Industries plc (NYSE: JHX) have certain options and for certain investors are short and strict deadlines running. Deadline: December 23, 2025. NYSE: JHX investors should contact the Shareholders
Investigation announced for Long-Term Investors in SelectQuote, Inc. (NYSE: SLQT)
Investigation announced for Long-Term Investors in SelectQuote, Inc. (NYSE: SLQT …
An investigation on behalf of current long-term investors in shares of SelectQuote, Inc. (NYSE: SLQT) concerning potential breaches of fiduciary duties by certain directors and officers of SelectQuote, Inc. was announced. Investors who are current long term investors in SelectQuote, Inc. (NYSE: SLQT) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term
Lawsuit filed for Investors who lost money with shares of MoonLake Immunotherapeutics (NASDAQ: MLTX)
Lawsuit filed for Investors who lost money with shares of MoonLake Immunotherape …
An investor, who purchased shares of MoonLake Immunotherapeutics (NASDAQ: MLTX), filed a lawsuit over alleged violations of Federal Securities Laws by MoonLake Immunotherapeutics in connection with certain allegedly false and misleading statements. Investors who purchased a significant amount of shares of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, have certain options and for certain investors are short and strict deadlines running. Deadline: December 15, 2025. NASDAQ:
Dow Inc. (NYSE: DOW) Investor Alert: Deadline in Lawsuit on October 28, 2025
Dow Inc. (NYSE: DOW) Investor Alert: Deadline in Lawsuit on October 28, 2025
A deadline is coming up on October 28, 2025 in the lawsuit filed for certain investors of Dow Inc. (NYSE: DOW) over alleged securities laws violations by Dow Inc. Investors who purchased shares of Dow Inc. (NYSE: DOW) have certain options and there are strict and short deadlines running. Deadline: October 28, 2025. Dow Inc. (NYSE: DOW) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -

All 5 Releases


More Releases for Atreca

Neuroendocrine Tumour Market is Expected to Show a Healthy Growth Rate During th …
DelveInsight's "Neuroendocrine Tumours Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Neuroendocrine Tumours, historical and forecasted epidemiology as well as the Neuroendocrine Tumours market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Download Sample Report to know more @https://www.delveinsight.com/sample-request/neuroendocrine-tumours-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr Neuroendocrine Tumour Overview Neuroendocrine tumors (NETs) are neoplasms that arise from cells of the endocrine (hormonal) and nervous systems. They most
Acral Lentiginous Melanoma Market is Expected to Show a Healthy Growth Rate Duri …
DelveInsight's "Acral lentiginous melanoma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Acral lentiginous melanoma, historical and forecasted epidemiology as well as the Acral lentiginous melanoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Download Sample Report to know more @https://www.delveinsight.com/sample-request/acral-lentiginous-melanoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr Acral Lentiginous Melanoma Overview Acral lentiginous melanoma is an aggressive type of skin cancer. Melanoma is a group
Immune Repertoire Sequencing Market 2023 | Futuristic Trends- Juno Therapeutics, …
The Immune Repertoire Sequencing report compiles the market information depending upon market development and growth factors, optimizing the growth path. In addition, it highlights the strategies and market share of the leading vendors in the particular market. The report follows a robust research methodology model that helps to make informed decisions. It obtains both qualitative and quantitative market information supported by primary research. The Immune Repertoire Sequencing research report recognizes and
Immune Repertoire Sequencing Market - Thermo Fisher Scientific, Inc., Illumina I …
Immune repertoire refers to sub-type protein that an organism’s immune system creates. Immune systems in vertebrates have six key types of proteins- two immunoglobulin and four T cell receptors. Immune repertoire sequencing enables researchers and scientists to examine and understand adaptive immune-mediated diseases. Immune repertoire sequencing is also widely applicable in biomarker discovery, infectious disease research, asthma and allergy research, and cancer immunotherapy. Click Here To Get Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/1517
Immune Repertoire Sequencing Market is Thriving Worldwide, Emerging Trends and T …
The global immune repertoire sequencing market is expected to reach USD 209.7 million by 2028 at a CAGR of 8.4% during the forecast period. Europe is expected to achieve the highest growth in the forecast period. The increased funding by the government alongside rising healthcare expenditure is expected to expand the size of the market in the region. Asia-Pacific region is also predicted to show immense growth of the market in
Immune Repertoire Sequencing Market to Surpass USD 209.7 million by 2028 | Adapt …
The global immune repertoire sequencing market is expected to reach USD 209.7 million by 2028 at a CAGR of 8.4% during the forecast period. In terms of region, North America is expected to hold a vast share of the market. Presence of a vast number of prominent players alongside growing attention towards novel technology for immune repertoire sequencing remains the key factor behind the growth of the market in the region.